Evidence map›Paper›PMID 30174861›Full record

ArticleJournal of thoracic disease2018

ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting.

Shirong Zhang, Lucheng Zhu, Xueqin Chen, Xiaochen Zhang, Enguo Chen, Hongming Fang, Yuejuan Feng, Yuping Li, Xi Wang, Zhongyu Jiang and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02623257 (A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02623257 completednot on this map

A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer

TypeobservationalSponsorFirst People's Hospital of HangzhouRan2016 to 2017Enrolled1,055ConditionsNon-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer MetastaticArmsmutation detection, ARMS, ctDNA analysis
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. CirculatingInternational journal of molecular sciences · 2022
    Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shirong ZhangDepartment of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Lucheng ZhuDepartment of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Xueqin ChenDepartment of Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Xiaochen ZhangDepartment of Medical Oncology, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Enguo ChenDepartment of Respiratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Hongming FangDepartment of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou 311202, China.
Yuejuan FengDepartment of Respiratory, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China.
Yuping LiDepartment of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, Hangzhou 325000, China.
Xi WangDepartment of Oncology, the 117th Hospital of PLA, Hangzhou 310013, China.
Zhongyu JiangDepartment of Oncology, Zhejiang Quhua Hospital, Quhua 324004, China.
Yina WangDepartment of Medical Oncology, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhihao ZhangDepartment of Oncology, Wujing Zhejiang Hospital, Hangzhou 310051, China.
Huijuan HeDepartment of Oncology, Quzhou People's Hospital, Quzhou 324000, China.
Shenglin MaDepartment of Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of EGFR mutations in circulating free tumor-derived DNA (ctDNA) was still unknown in China. This large-scale study (NCT02623257) aimed to explore the prevalence of epidermal growth factor receptor (EGFR) mutations and determine the correlation of EGFR mutation status with clinical characteristics.

methodsPlasma DNA samples from 1,001 patients with stage III/IV NSCLC who received ≤1st line chemotherapy were collected from 65 hospitals. EGFR mutations were tested by amplification refractory mutation system (ARMS) method. The EGFR mutation rate was calculated and the associations between EGFR status and patients' demographic data, disease status as well as treatment pattern were explored.

resultsEGFR mutations were detected in 251 of 1,001 (25.1%) patients, 26.8% in adenocarcinoma and 11.7% in squamous carcinoma. A total of 189 harbored sensitizing mutations alone, 28 had resistance mutations alone, 3 had a combination of activating mutations, and 31 had a combination of activating and resistance mutations. Higher detection rate was observed in chemotherapy-naïve patients than those received 1st line chemotherapy (27.0%

conclusionsctDNA based EGFR mutation test is feasible and could be a surrogate when tissue biopsy is not available.

Indexed as

amplification refractory mutation system (ARMS)circulating free tumor-derived DNA (ctDNA)Epidermal growth factor receptor (EGFR)lung cancer

Identifiers

PMID30174861
PMCPMC6105939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.